Resources Repository
-
BookPublication 2002Prevention Effectiveness: Guide to Decision Analysis and Economic Evaluation, 2nd Edition
This book was originally written to introduce Centers for Disease Control and Prevention staff to …
This book was originally written to introduce Centers for Disease Control and Prevention staff to the concepts of decision and economic analysis, to provide guidance on methods to maximize comparability of studios, and to provide access to frequently used reference information. It has been adapted to meet the needs of scientists and managers in state and local health departments and managed care organizations as well as students in schools of public health and clinicians for…
Probability/Bayes | Benefit-Cost Analysis | North America | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Economics/Finance | Health/Medicine | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Benefit-Cost Analysis | North America | Mathematical Models | State-Transition | Infectious Diseases | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | North America | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | North America | Value of Information | State-Transition | Infectious Diseases | Policy/Regulation | Economics/Finance | Europe -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | North America | Preferences/Values | Infectious Diseases | Policy/Regulation | Government/Law -
ArticlePublication 2021COVID and the Age–VSL Relationship
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions …
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions in analyses of lockdowns and other policies. Many rely on a population-average estimate of the value per statistical life (VSL); others adjust VSL for life expectancy at the age of death. The article explores the implications of theory and empirical studies, which suggest that the relationship between age and VSL is uncertain; these uncertainties in turn may affect whether the…
Benefit-Cost Analysis | North America | Preferences/Values | Infectious Diseases | Government/Law | Health/Medicine -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | North America | Test Performance | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Global -
ArticlePublication 2001Cost-Benefit Analysis of a Strategy to Vaccinate Healthy Working Adults against Influenza
The authors performed a cost-benefit analysis to assess the economic impact of vaccinating healthy working …
The authors performed a cost-benefit analysis to assess the economic impact of vaccinating healthy working adults between 18 and 64 years old with an influenza vaccine. Monte Carlo simulation was used to calculate the direct and indirect costs associated with vaccination and those prevented by vaccination. The authors found that vaccinating healthy working adults was, on average, cost-saving.
Benefit-Cost Analysis | North America | Infectious Diseases | Health/Medicine -
Lesson/ModuleVideo, Teaching Resource 2018Estimating Transition Probabilities for a Model
This video is intended to provide a discussion on various methods for deriving probabilities that are …
This video is intended to provide a discussion on various methods for deriving probabilities that are needed for decision models. Presented are the concepts of literature based Odds Ratios and Relative Risks, which need to be transformed into probabilities, how to deal with probability estimates from time frames not relevant to the model in question, and how to derive probabilities from published summary statistics. This lecture is aimed at the researcher who is interested in operationalizing…
Probability/Bayes | North America | Evidence Synthesis | Mathematical Models | Health/Medicine | College | Graduate | Doctoral | Critical Thinking/Analysis | Quantitative Literacy